Adaptive phenotypic modulations lead to therapy resistance in chronic myeloid leukemia cells

Hybrid epithelial/mesenchymal phenotype(s): The ‘fittest’ for metastasis?

(2018) Mohit Kumar Jolly et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

E-cadherin: Its dysregulation in carcinogenesis and clinical implications

(2018) Sonia How Ming Wong et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Epithelial-to-mesenchymal transition in tumor progression

(2017) Elena Prieto-García et al.   MEDICAL ONCOLOGY

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

(2017) Andreas Hochhaus et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-Term Exposure to Imatinib Mesylate Downregulates Hippo Pathway and Activates YAP in a Model of Chronic Myelogenous Leukemia

(2017) Anna Chorzalska et al.   STEM CELLS AND DEVELOPMENT

Decreased Expression of Caveolin-1 and E-Cadherin Correlates with the Clinicopathologic Features of Gastric Cancer and the EMT Process

(2016) Kundong Zhang et al.   Recent Patents on Anti-Cancer Drug Discovery

Syntenin regulates TGF-β1-induced Smad activation and the epithelial-to-mesenchymal transition by inhibiting caveolin-mediated TGF-β type I receptor internalization

(2015) C Hwangbo et al.   ONCOGENE

Enhanced G2/M Arrest, Caspase Related Apoptosis and Reduced E-Cadherin Dependent Intercellular Adhesion by Trabectedin in Prostate Cancer Stem Cells

(2015) Eda Acikgoz et al.   PLoS One

Phenotype Switching: Tumor Cell Plasticity as a Resistance Mechanism and Target for Therapy

(2014) K. Kemper et al.   CANCER RESEARCH

The metabolically-modulated stem cell niche: a dynamic scenario regulating cancer cell phenotype and resistance to therapy

(2014) Elisabetta Rovida et al.   CELL CYCLE

CAV-1 contributes to bladder cancer progression by inducing epithelial-to-mesenchymal transition

(2014) Wu Liang et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Resistance to Tyrosine Kinase Inhibition Therapy for Chronic Myelogenous Leukemia: A Clinical Perspective and Emerging Treatment Options

(2013) Elias J. Jabbour et al.   Clinical Lymphoma Myeloma & Leukemia

The Culture-Repopulating Ability Assays and Incubation in Low Oxygen: A Simple Way to Test Drugs on Leukaemia Stem or Progenitor Cells

(2013) Maria Cipolleschi et al.   CURRENT PHARMACEUTICAL DESIGN

Multi-Drug–Resistant Cells Enriched From Chronic Myeloid Leukemia Cells by Doxorubicin Possess Tumor-Initiating–Cell Properties

(2013) Hong Xin et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

Pharmacokinetics of dasatinib for Philadelphia-positive acute lymphocytic leukemia with acquired T315I mutation

(2012) Naoto Takahashi et al.   Journal of Hematology & Oncology

Imatinib triggers mesenchymal-like conversion of CML cells associated with increased aggressiveness

(2012) Alexandre Puissant et al.   Journal of Molecular Cell Biology

A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects

(2011) Richat Abbas et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Monitoring response and resistance to treatment in chronic myeloid leukemia

(2011) S. Assouline et al.   Current Oncology

Wnt signaling in hematopoiesis: Crucial factors for self-renewal, proliferation, and cell fate decisions

(2010) Frank J.T. Staal et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity

(2010) Amie S. Corbin et al.   JOURNAL OF CLINICAL INVESTIGATION

Epigenetic reprogramming and induced pluripotency

(2009) K. Hochedlinger et al.   DEVELOPMENT

The basics of epithelial-mesenchymal transition

(2009) Raghu Kalluri et al.   JOURNAL OF CLINICAL INVESTIGATION

Molecular biology of bcr-abl1-positive chronic myeloid leukemia

(2008) A. Quintas-Cardama et al.   BLOOD

Nilotinib

(2008) M. W. Deininger   CLINICAL CANCER RESEARCH